Dr Lawrence P Alejandre, PHARMD | |
275 Kenyon Ave, Kensington, CA 94708-1028 | |
(510) 527-4307 | |
Not Available |
Full Name | Dr Lawrence P Alejandre |
---|---|
Gender | Male |
Speciality | Pharmacist - Pharmacist Clinician (phc)/ Clinical Pharmacy Specialist |
Location | 275 Kenyon Ave, Kensington, California |
Accepts Medicare Assignments | Does not participate in Medicare Program. He may not accept medicare assignment. |
Identifier | Type | State | Issuer |
---|---|---|---|
1447597026 | NPI | - | NPPES |
Taxonomy | Type | License (State) | Status |
---|---|---|---|
1835P0018X | Pharmacist - Pharmacist Clinician (phc)/ Clinical Pharmacy Specialist | 31357 (California) | Primary |
Mailing Address | Practice Location Address |
---|---|
Dr Lawrence P Alejandre, PHARMD 275 Kenyon Ave, Kensington, CA 94708-1028 Ph: (510) 527-4307 | Dr Lawrence P Alejandre, PHARMD 275 Kenyon Ave, Kensington, CA 94708-1028 Ph: (510) 527-4307 |
News Archive
MedPro Safety Products, Inc., a leading developer of transformational technologies that enable safer medication delivery and blood collection, announced today that it has completed the issuance of a final $5 million tranche of Senior Secured 14% Notes due 2016 in a private placement with institutional investors.
The most effective prescription drug used to quit smoking initially helps women more than men, according to a Yale School of Medicine study. The study, published Oct. 7 by the journal Nicotine and Tobacco Research, found that varenicline, marketed as Chantix, was more effective earlier in women, and equally effective in women and men after one year.
A new international study for women with HER2-positive breast cancer is open for enrollment. The pivotal BETH (BEvacizumab and Trastuzumab Adjuvant Therapy in HER2-positive Breast Cancer) study is a Phase III clinical research trial that is investigating the benefits of combining two monoclonal antibodies, the anti-angiogenic, bevacizumab (Avastin) and the targeted therapy trastuzumab (Herceptin), together with chemotherapy for the treatment of patients with early stage HER2-positive breast cancer.
Some cases of recurrent pregnancy loss may be caused by sperm DNA damage in the male partner, rather than by a problem in affected women, according to research to be presented Sunday, March 24 at ENDO 2019, the Endocrine Society's annual meeting in New Orleans, La.
Nearly 80 percent of peanut-allergic preschool children successfully incorporated peanut-containing foods into their diets after receiving peanut oral immunotherapy (OIT), a clinical trial has found.
› Verified 7 days ago
Dr. Sharon N. Hashimoto, PHARM.D. Pharmacist Medicare: Not Enrolled in Medicare Practice Location: 275 Kenyon Ave, Kensington, CA 94708 Phone: 510-527-4307 |